The Ovarian Cancer Canada Breakthrough Fund 2026 supports pragmatic clinical trials advancing ovarian cancer early detection or precision treatment. These studies test interventions in routine healthcare settings, producing evidence relevant to everyday clinical practice.
The competition offers two grants and requires meaningful patient involvement, an outlined pathway to commercialization, and consideration of equity, diversity and inclusion in study design.
Eligibility Criteria
- Principal applicants must hold research positions at Canadian academic institutions.
- Applicants must be eligible to hold institutional research funds.
- International co-applicants and collaborators are permitted, but funds must be spent in Canada.
- Projects must use a pragmatic clinical trial design.
- Research must address ovarian cancer early detection or precision treatment.
- Endometrial cancer may be included if the study also directly benefits ovarian cancer patients.
- Patients or people with lived experience must participate as research partners.
- Proposals must address commercialization potential and inclusive study design.
Funding Details
- Maximum: CAD $500,000 per project over two years.
- Total pool: CAD $1 million.
- Institutional indirect costs and investigator remuneration are excluded.
- Funding begins: On or before March 31, 2027.
Deadline
- November 30, 2026, at 11:59 PM Eastern Time.
Further Information
- Complete the online registration and email the full application as one PDF to jlawson@ovariancanada.org.
- Official programme and registration
- Competition guidelines